Callisto Announces Trial of Atiprimod in Patients With Advanced Cancer

Callisto Pharmaceuticals, a biopharmaceutical company primarily focused on the development of drugs to treat cancer and osteolytic bone disease, has announced a second clinical trial of Atiprimod, its lead drug presently in a Phase I/IIa trial in relapsed multiple myeloma patients.

The new trial, titled "An Open Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients with Advanced Cancer," is designed to assist in finding the maximum-tolerated dose of Atiprimod in advanced cancer patients and to assess the drug's activity in solid tumors and hematologic malignancies.